Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥679.7bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥620.8bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥4.1bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥1.9bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.8bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥5.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥740.6bnat 2022-09-30Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥695.9bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥495.0bnat 2022-09-30Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥240.7bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥102.1bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥88.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.392021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.842021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥42.622021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.5%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥654.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥631.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥708.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥679.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥4.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥996m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-09-30¥45.5bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-09-30¥45.4bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥5m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-09-30¥819m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-09-30¥312m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-09-30¥597.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-09-30¥572.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥2.7bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥667m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥100m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥649.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥620.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 580
ItemContextValueUnit
Current liabilitiesPrior1YearInstant402819000000JPY
Current liabilitiesCurrentQuarterInstant452792000000JPY
Bonds payablePrior1YearInstant20023000000JPY
Bonds payableCurrentQuarterInstant－JPY
Long term loans payablePrior1YearInstant12596000000JPY
Long term loans payableCurrentQuarterInstant14759000000JPY
Net defined benefit liabilityPrior1YearInstant2423000000JPY
Net defined benefit liabilityCurrentQuarterInstant2451000000JPY
Asset retirement obligations nclPrior1YearInstant2741000000JPY
Asset retirement obligations nclCurrentQuarterInstant2753000000JPY
Provision for loss on anti monopoly act nclPrior1YearInstant3639000000JPY
Provision for loss on anti monopoly act nclCurrentQuarterInstant5039000000JPY
Other nclPrior1YearInstant16850000000JPY
Other nclCurrentQuarterInstant17213000000JPY
Noncurrent liabilitiesPrior1YearInstant58275000000JPY
Noncurrent liabilitiesCurrentQuarterInstant42215000000JPY
LiabilitiesPrior1YearInstant461095000000JPY
LiabilitiesCurrentQuarterInstant495007000000JPY
Capital stockPrior1YearInstant10649000000JPY
Capital stockCurrentQuarterInstant10649000000JPY
Capital surplusPrior1YearInstant49228000000JPY
Capital surplusCurrentQuarterInstant49145000000JPY
Retained earningsPrior1YearInstant180254000000JPY
Retained earningsCurrentQuarterInstant182769000000JPY
Treasury stockPrior1YearInstant-15719000000JPY
Treasury stockCurrentQuarterInstant-15719000000JPY
Shareholders equityPrior1YearInstant224413000000JPY
Shareholders equityCurrentQuarterInstant226846000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant20792000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant22838000000JPY
Revaluation reserve for landPrior1YearInstant-4273000000JPY
Revaluation reserve for landCurrentQuarterInstant-4276000000JPY
Valuation and translation adjustmentsPrior1YearInstant16518000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant18561000000JPY
Subscription rights to sharesPrior1YearInstant149000000JPY
Subscription rights to sharesCurrentQuarterInstant148000000JPY
Non controlling interestsPrior1YearInstant199000000JPY
Non controlling interestsCurrentQuarterInstant85000000JPY
Net assetsPrior1YearInstant241281000000JPY
Net assetsCurrentQuarterInstant245642000000JPY
Liabilities and net assetsPrior1YearInstant702376000000JPY
Liabilities and net assetsCurrentQuarterInstant740650000000JPY
Net salesPrior1YTDDuration620845000000JPY
Net salesCurrentYTDDuration679719000000JPY
Cost of salesPrior1YTDDuration570278000000JPY
Cost of salesCurrentYTDDuration626812000000JPY
Gross profitPrior1YTDDuration50566000000JPY
Gross profitCurrentYTDDuration52907000000JPY
Directors compensations salaries and allowances sgaPrior1YTDDuration20208000000JPY
Directors compensations salaries and allowances sgaCurrentYTDDuration20136000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass